Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER versus SUPRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER versus SUPRAX.
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER vs SUPRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in cell lysis and death.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1 to 2 g intravenously every 12 hours for 5 to 10 days. For severe infections, 2 g intravenously every 12 hours.
400 mg orally once daily or 200 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life 3-4 hours in normal renal function; prolonged in renal impairment (e.g., up to 13 hours in severe renal failure).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 11-15 hours in severe renal impairment (CrCl <20 mL/min).
Primarily renal (unchanged drug) ~88%; minor biliary/fecal ~6-9%.
Renal: 50-55% unchanged in urine; biliary/fecal: 10-20% (biliary excretion); remainder metabolized or excreted via feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic